Armstrong Fleming & Moore’s Novo Nordisk NVO Stock Holding History

Armstrong Fleming & Moore’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Buy	+5,173	New	+$222K	0.08%	97
2026 Q1	–	Sell	-5,878	Closed	-$299K	–	111
2025 Q4	$299K	Sell	5,878 -234	-4%	-$12K	0.14%	77
2025 Q3	$339K	Buy	6,112 +806	+15%	+$47.2K	0.16%	79
2025 Q2	$366K	Buy	+5,306	New	+$361K	0.2%	69
2025 Q1	–	Sell	-5,924	Closed	-$510K	–	135
2024 Q4	$510K	Sell	5,924 -1,608	-21%	-$174K	0.31%	55
2024 Q3	$897K	Buy	7,532 +500	+7%	+$66.7K	0.52%	38
2024 Q2	$1M	Buy	7,032 +2,374	+51%	+$315K	0.64%	28
2024 Q1	$598K	Hold	4,658	–	–	0.41%	46
2023 Q4	$482K	Hold	4,658	–	–	0.36%	54
2023 Q3	$424K	Buy	4,658 +330	+8%	+$29.1K	0.41%	54
2023 Q2	$350K	Buy	+4,328	New	+$354K	0.32%	63

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Armstrong Fleming & Moore's NVO Position: Q2 2026 in Review

Armstrong Fleming & Moore opened a new position in Novo Nordisk (NVO) in Q2 2026: 5,173 shares worth $248K. The stake represents 0.08% of the portfolio and ranks #97 among its holdings. This is a return to the name: Armstrong Fleming & Moore previously reported a position in NVO as recently as Q4 2025.

Armstrong Fleming & Moore first reported a position in NVO in Q2 2023 and has held it in 11 quarters since. The position peaked at $1M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Armstrong Fleming & Moore held 5,173 shares of Novo Nordisk worth $248K as of Q2 2026.
Novo Nordisk was a new Armstrong Fleming & Moore position in Q2 2026.
Novo Nordisk made up 0.08% of Armstrong Fleming & Moore's portfolio in Q2 2026, its #97 holding.
Armstrong Fleming & Moore first reported a position in Novo Nordisk in Q2 2023 and has held it in 11 quarters since.
Armstrong Fleming & Moore's Novo Nordisk position peaked at $1M in Q2 2024.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Armstrong Fleming & Moore's 13F filing for Q2 2026, filed 28 Jul 2026.